FPT-SOFTWARE
31.7.2024 04:01:26 CEST | Business Wire | Press release
Global leading IT company FPT Software announced that its Chief Artificial Intelligence Officer, Dr. Nguyen Xuan Phong, has been listed on the 2024-2025 Artificial Intelligence 150 (AI150) list by Constellation Research, recognizing leaders pioneering AI transformation efforts around the globe. The Chief AI Officer is the only executive from a Southeast Asian enterprise to be named to this elite list.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730156983/en/
(Graphic: Business Wire)
2024-2025 Artificial Intelligence 150 (AI150) is an inaugural initiative by Constellation Research, a technology research and advisory firm based in Silicon Valley and one of the world’s leaders in digital transformation and disruptive technology consulting. The AI150 celebrates top global executives leading AI transformation efforts globally, across multiple industries, and in various roles including Chief AI Officer, Chief Digital Officer, Chief Technology Officer, and Chief Executive Officer.
The selection process lasts six months, from nomination by industry leaders to extensive reference checks for real projects, leadership, mentorship abilities, and standing among colleagues and peer groups. Each leader on the AI150 demonstrates a comprehensive understanding of how the world is responding to artificial intelligence and how new technologies can be leveraged for future innovation.
The accolade is a testament to Dr. Nguyen Xuan Phong and FPT Software’s commitment to being a pioneer, practitioner, and advocate for the acceleration of Intelligence Transformation while using AI to address key business and technology challenges of global enterprises. Others featured in the 2024-2025 list include executives from global technology leaders like SAP, Adobe, Google, Intel, Facebook, and Microsoft, as well as Fortune 500 enterprises such as Ford Motor, United Airlines, TotalEnergies, Merck, and Schneider Electric.
FPT Software and its parent company, FPT Corporation, have over a decade of experience in the research and development of AI solutions since the establishment of its first AI Research Lab in 2019, serving as a comprehensive research, development, and learning facility for 20,000 tech personnel. In his role, Dr. Nguyen Xuan Phong heads a robust global AI Center that drives AI research and industrial application for FPT Software’s global clients, strategizing AI integration, fostering innovation, boosting productivity, and ensuring ethical AI practices. He played an instrumental role in FPT Corporation’s global partnerships with leading AI players such as NVIDIA, Mila, Landing AI, AITOMATIC, and the recent founding membership of the AI Alliance led by IBM and Meta.
“At FPT Software, we believe AI is not just about algorithms; it’s about transforming organizations, industries, and people’s lives. We are committed to expanding our AI ecosystems and embedding AI and Generative AI into all of our solutions and services, as this technology will fundamentally transform everything in business and our society,” said Dr. Nguyen Xuan Phong. “It is my pleasure to be recognized in this esteemed list, and I look forward to engaging with Constellation Research and the AI150 community to participate in global conversations and research studies on AI and business transformation.”
“In the Age of AI, we can expect AI to be infused in every part of the business. This rapidly evolving field has pioneers, policy shapers, and practitioners that will transform industries,” noted R “Ray” Wang, founder and CEO at Constellation Research. “The AI150 is our attempt of identifying a small slice of the innovators and change agents that are making substantial contributions to the advancement of this revolution.”
In addition to his work with FPT Software, Dr. Nguyen Xuan Phong is a decorated scholar with a PhD/EngD from the University of Tokyo, majoring in AI. He also made significant contributions to AI research at Hitachi in Japan and the Mila, Quebec AI Institute in Canada.
The full listing can be found here: Artificial Intelligence 150 2024 - 2025 | Constellation Research Inc.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730156983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom